Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908122 | 0.89 | ALOX15 (0.50) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL2910558 | 0.88 | PLA2G2A (0.54) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL5717584 | 0.88 | GRM2 (0.55) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL2908545 | 0.85 | MCL1 (0.53) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL15129579 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL2908071 | 0.84 | KDM4E (0.59) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL2658663 | 0.83 | CTSL (0.62) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL27685906 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL24915721 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL2904860 | 0.81 | DHODH (0.52) | HSD17B10LMNAALOX15DHODHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022134733-A1 | USE OF COMPOUND CAPABLE OF INHIBITING INTERACTION OF CORONAVIRUS SPIKE PROTEIN WITH ACE2 | 中国药科大学 | 2022-06-30 | — | — | WO | disclosed |
| CN-112245428-B | Application of compound capable of inhibiting interaction of coronavirus Spike protein and ACE2 | 中国药科大学 | 2021-03-19 | — | — | CN | disclosed |
| CN-112245428-A | Application of compound capable of inhibiting interaction of coronavirus Spike protein and ACE2 | 中国药科大学 | 2021-01-22 | — | — | CN | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| EP-2428506-B1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| EP-1578423-B1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052366-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | WO | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-5344922-A | 4-hydroxyquinaldic acid derivatives | BOARD OF REGENTS, UNIVERSITY OF TEXAS | 1994-09-06 | — | — | US | disclosed |
| US-5028707-A | 4-hydroxyquinaldic acid derivatives | BOARD OF REGENTS, UNIVERSITY OF TEXAS (US) | 1991-07-02 | — | — | US | disclosed |
| WO-1991007390-A1 | 4-HYDROXYQUINALDIC ACID DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | KDM4E 4333/4885ALDH1A1 745/4885HSD17B10 3757/4885 |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | KDM4E 1618/4885ALDH1A1 112/4885HSD17B10 1021/4885 |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, ADORA1, P2RY1 | KDM4E 4372/4885ALDH1A1 817/4885HSD17B10 4098/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | KDM4E 4378/4885ALDH1A1 585/4885HSD17B10 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.